Raymond James Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Raymond James Financial’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.57M	Buy	365,297 +46,714	+15%	+$273K	﹤0.01%	3687
2026 Q2	$2.55M	Sell	318,583 -206,641	-39%	-$1.78M	﹤0.01%	3312
2026 Q1	$4.22M	Sell	525,224 -40,832	-7%	-$391K	﹤0.01%	2734
2025 Q4	$6.59M	Sell	566,056 -190,291	-25%	-$1.85M	﹤0.01%	2289
2025 Q3	$7.6M	Buy	756,347 +82,977	+12%	+$1.19M	﹤0.01%	2139
2025 Q2	$11.8M	Sell	673,370 -33,417	-5%	-$482K	﹤0.01%	1744
2025 Q1	$8.89M	Buy	706,787 +83,506	+13%	+$1M	﹤0.01%	1905
2024 Q4	$6.58M	Buy	+623,281	New	+$8.73M	﹤0.01%	2146

Other funds holding SPRY

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Tyro Capital Management Miami, Florida $564M AUM 72.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return

Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return

Raymond James Financial's SPRY Position: Q3 2026 in Review

Raymond James Financial increased its ARS Pharmaceuticals (SPRY) stake by 15% in Q3 2026, buying an estimated $273K and bringing the position to 365,297 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3687.

Raymond James Financial first reported a position in SPRY in Q4 2024 and has held it in 8 quarters since. The position peaked at $11.8M in Q2 2025. 133 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

Raymond James Financial held 365,297 shares of ARS Pharmaceuticals worth $1.57M as of Q3 2026.
Raymond James Financial bought 46,714 ARS Pharmaceuticals shares in Q3 2026, an estimated $273K.
ARS Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3687 holding.
Raymond James Financial first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
Raymond James Financial's ARS Pharmaceuticals position peaked at $11.8M in Q2 2025.
133 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.